News

Markets are wrestling with a Fed that sounds more willing to tolerate economic pain than investors expected, while supply shocks from oil and tariffs keep pressure on costs. That mix tends to push attention toward reliable cash flows and dividends, as many traders reassess how much risk they really want to hold. This article walks through three large-cap, income-focused stocks exposed to this macro backdrop and explains how each may factor into your portfolio decisions now. The stocks below...

Abbott Laboratories (NYSE:ABT) reached a US$385 million settlement tied to the 2022 infant formula recall and Sturgis plant shutdown. The agreement resolves civil claims from families, states, and other plaintiffs alleging product safety failures and gaps in compliance with federal standards. The settlement follows U.S. Department of Justice and multi state investigations into Abbott's infant formula operations, with no admission of liability. This civil resolution of Abbott's 2022 formula...

Some federal prosecutors believed there was enough evidence to bring criminal charges, but Justice Department leadership opted for a civil settlement.

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.

Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.

Three catalysts, one reshuffling, and a Fed that refuses to move

These stocks can help you withstand (almost) any storm.

Matrix Asset Advisors, an asset management company, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The stock market rebounded strongly in the second quarter, with the S&P 500 gaining 15.2% in the quarter and 10.2% year-to-date. Investors overlooked inflation concerns exceeding 4% and geopolitical tensions, focusing instead on […]

July 29 () - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its ‌diagnostic and imaging devices and refunds of tariffs imposed under U. Shares of the medical device maker rose 12% in premarket trading.

July 29 (Reuters) - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its diagnostic and imaging devices and refunds of tariffs imposed ​

The Morning Bull - US Market Morning Update Friday, Jul, 17 2026 US stock futures are drifting slightly lower this morning, with key index contracts such as the E-mini S&P 500 and Nasdaq-100 off by around 0.1% to 0.4%, as investors weigh tighter financial conditions against mixed global growth signals. A planned 25% US tariff on some Brazilian imports raises questions about costs for companies tied to global trade and agriculture, while US crude stockpiles and the Strategic Petroleum Reserve...

Today Earnings (a.m): UnitedHealth, GE Aerospace, U.S. Bancorp, Citizens Financial, Abbott Laboratories, State Street, Taiwan Semiconductor Manufacturing Earnings (p.m.): Netflix, Intuitive Surgical Economic data: Weekly jobless claims, Philadelphia Fed business-outlook survey, retail sales, pending home sales index, business inventories Fed speakers: Fed Vice Chair Philip Jefferson is expected to speak, as is Dallas Fed President Lorie Logan.

Today Earnings: Johnson & Johnson, Morgan Stanley, BlackRock, PNC Financial Services, Conagra, Cintas, United Airlines, Bank of New York Mellon, Elevance Health, J.B. Hunt, ASML Economic data: Producer-price index data for June, Empire State manufacturing survey, EIA weekly petroleum status report, Fed beige book.

Abbott Laboratories (NYSE:ABT) is among the Best Brain-Computer Interface Stocks. On June 4, Reuters reported a federal judge ‌ruled that Abbott Laboratories (NYSE:ABT) must face a proposed class-action lawsuit alleging it misled consumers by marketing PediaSure Grow & Gain drinks as “clinically proven” to help children grow. US District Judge Paul Engelmayer said labeling featuring a […]

Abbott Laboratories (NYSE:ABT) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give a retirement-focused portfolio something rare: cash compounding that does not require monitoring. Pillar One: Durability Built Into the Business Model Abbott’s revenue flows from four distinct segments ... Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat

Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. A caller asked about Cramer’s thoughts on the stock, and he replied: Now, I gotta tell you something, I was shocked at the decline […]

MDT trades at about 14x forward earnings with a 3.5% yield as fiscal 2027 guidance points to steady growth, but margins face tariffs and mix pressure.

Carillon Tower Advisers, an investment management company, released its first-quarter 2026 investor letter for the “Carillon Eagle Growth & Income Fund”. A copy of the letter is available to download here. The first quarter of 2026 was volatile due to market shifts, including increased geopolitical risk and inflation fears from rising energy prices. The S&P declined […]

They have increased their payouts for a combined 171 years straight.